Evolving Cardiac Safety in Drug Discovery: Time for Immunology Integration

Circulation. 2024 May 28;149(22):1704-1707. doi: 10.1161/CIRCULATIONAHA.123.068383. Epub 2024 May 28.

Authors

Jose M Vicencio¹, Caroline R Archer¹, Amy Pointon¹

Affiliation

¹ Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.

PMID: 38805578
DOI: 10.1161/CIRCULATIONAHA.123.068383

No abstract available

Keywords: cardio-oncology; cardiotoxicity; heart failure; immune checkpoint inhibitors; immunotherapy; microphysiological systems; organ-on-chip.

MeSH terms

Animals
Cardiotoxicity / etiology
Drug Discovery*
Humans